WayPoint Biomedical Acquires First Sales Order Contract for The Drink Detective from Florida Based Drug Screen Solutions


HUNTINGTON BEACH, Calif., July 11, 2005 (PRIMEZONE) -- WayPoint Biomedical Corporation (Pink Sheets:WYPB) has booked its first sales contract with Florida based Drug Screen Solutions, for WayPoint's flagship product, The Drink Detective(tm) drink spiking drug detection kit. Drug Screen Solutions (www.drugscreensolutions.com) will market the product via their e-commerce website, as well as through their professional sales network into Florida nightclubs, beverage distributors, colleges/schools, retail chains, and government/law enforcement agencies.

The Drink Detective(tm):

The Drink Detective(tm) provides a revolutionary new tool to fight drink spiking, along with providing enhanced public awareness, and a true deterrent to the crime. This highly affordable, credit card sized test kit can be used to detect over sixty different illicit drugs, including Ketamine, GHB and Rohypnol(r), that can be used for spiking alcoholic or non-alcoholic drinks.

In December of last year, The Drink Detective(tm) won the prestigious "Best of What's New 2004" award for the Personal Health category in Popular Science Magazine. The Drink Detective(tm) has also aired on the nationally syndicated "Life & Style" program by Sony Pictures Television in February 2005, detailing the social awareness of "Date-Rape" and how the Drink Detective(tm) can assist in preventing such criminal activity.

About WayPoint Biomedical:

WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (Pink Sheets:WYPB), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit www.waypointbiomedical.com, www.drinkdetectiveusa.com.

Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.


            

Contact Data